Business
IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial
POTOMAC, MARYLAND / ACCESS Newswire / August 19, 2025 /IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, reported its financial ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MARYLAND / ACCESS Newswire / August 19, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, reported its financial results for the quarter ended June 30, 2025.","length":321,"tagName":"p"},{"type":"text","content":"Highlights in the quarter include:","length":34,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Accelerated progress on the Company's Phase 2 CALMA trial in Alzheimer's disease","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Progress in the development of MINT-AD","length":38,"tagName":"p"}]},{"val":[{"type":"text","content":"Extension of its undrawn $12M credit facility","length":45,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":171,"olType":false},{"type":"text","content":"Ram Mukunda, CEO of IGC Pharma, commented, "We began fiscal 2026 with solid strategic momentum, advancing multiple programs that we believe position IGC for meaningful value creation this fiscal year. Our Phase 2 CALMA trial for IGC-AD1, a cannabinoid-based proprietary formulation with the potential to address agitation, a debilitating symptom affecting up to 76% of Alzheimer's patients, continues to progress toward critical milestones in the FDA clinical trial process. In parallel, our non-cannabinoid platforms, TGR-63 and IGC-M3, are moving through preclinical development with the goal of addressing underlying disease modification. We also made progress with MINT-AD, by increasing the number of harmonized databases and training algorithms. MINT-AD is our first-of-its-kind AI-driven physician's tool to help identify and stratify Alzheimer's risk factors and predict cognitive decline, which we believe can help the over 400 million individuals with early Alzheimer's pathology who are at risk for Alzheimer's."","length":1053,"tagName":"p"},{"type":"text","content":"Q1 FY2026 Company's Highlights:","length":35,"tagName":"p"},{"type":"text","content":"Strategic & Operational Highlights","length":38,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"During the quarter, IGC expanded trial sites across North America (Ontario, FL, RI, PR, OK) to support enrollment in the CAL...